Crossmark

Tolerance and effectiveness of inhaled antibiotics at standard or low doses in COPD patients with chronic Pseudomonas aeruginosa bronchial infection

Crossref DOI link: https://doi.org/10.1038/s41598-025-91763-w

Published Online: 2025-03-13

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Costa, Roser

Navarro, Annie

Leal, Miguel Ángel

Hernández, Andrea

Esquinas, Cristina

Miravitlles, Marc
License Information

Text and Data Mining valid from 2025-03-13

Version of Record valid from 2025-03-13
More Information

Article History

Received: 23 July 2024

Accepted: 24 February 2025

First Online: 13 March 2025

Declarations

:

: Marc Miravitlles has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Menarini, Kamada, Takeda, Zambon, CSL Behring, Specialty Therapeutics, Janssen, Grifols and Novartis, consulting fees from AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, BEAM Therapeutics, Chiesi, GlaxoSmithKline, CSL Behring, Ferrer, Inhibrx, Menarini, Mereo Biopharma, Spin Therapeutics, Specialty Therapeutics, ONO Pharma, Palobiofarma SL, Takeda, Novartis, Novo Nordisk, Sanofi, Zambon, Zentiva and Grifols and research grants from Grifols. Annie Navarro has received speaker fees from AstraZeneca, Chiesi, Cipla, GlaxoSmithKline and Zambon. Miguel Ángel Leal has received speaker fees from AstraZeneca and Chiesi.Roser Costa has received speaker fees from Novartis, AstraZeneca, Chiesi, GlaxoSmithKline, Zambon and Bial. The remaining authors report no conflicts of interest in this work.

: Annie Navarro has received speaker fees from AstraZeneca, Chiesi, Cipla, GlaxoSmithKline and Zambon.

: Miguel Ángel Leal has received speaker fees from AstraZeneca and Chiesi.

: Roser Costa has received speaker fees from Novartis, AstraZeneca, Chiesi, GlaxoSmithKline, Zambon and Bial.

: The remaining authors report no conflicts of interest in this work.

Document is current

Any future updates will be listed below